Arrowhead Pharmaceuticals, Inc.
ARWR
$82.63
-$2.48-2.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 669.50M | 622.01M | 1.09B | 829.45M | 572.98M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 669.50M | 622.01M | 1.09B | 829.45M | 572.98M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 669.50M | 622.01M | 1.09B | 829.45M | 572.98M |
| SG&A Expenses | 184.47M | 167.74M | 153.54M | 134.55M | 124.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 895.93M | 843.90M | 790.41M | 731.10M | 680.94M |
| Operating Income | -226.44M | -221.90M | 300.57M | 98.35M | -107.96M |
| Income Before Tax | -252.08M | -252.26M | 254.92M | 51.53M | -157.39M |
| Income Tax Expenses | 20.05M | 19.60M | 21.35M | 21.42M | 1.97M |
| Earnings from Continuing Operations | -272.13 | -271.86 | 233.57 | 30.11 | -159.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -47.83M | -29.05M | -31.31M | -31.75M | 10.93M |
| Net Income | -319.95M | -300.91M | 202.27M | -1.63M | -148.42M |
| EBIT | -226.44M | -221.90M | 300.57M | 98.35M | -107.96M |
| EBITDA | -200.64M | -196.53M | 325.65M | 122.27M | -85.40M |
| EPS Basic | -2.23 | -2.14 | 1.57 | -0.04 | -1.24 |
| Normalized Basic EPS | -1.52 | -1.41 | 0.99 | -0.01 | -0.73 |
| EPS Diluted | -2.25 | -2.15 | 1.54 | -0.07 | -1.27 |
| Normalized Diluted EPS | -1.52 | -1.42 | 0.97 | -0.03 | -0.75 |
| Average Basic Shares Outstanding | 560.71M | 556.37M | 547.32M | 535.13M | 521.61M |
| Average Diluted Shares Outstanding | 564.38M | 560.04M | 552.11M | 536.25M | 522.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |